NICE 'unable to recommend' Forxiga
The U.K.'s NICE said in draft guidance that it was "unable to recommend" the use of Forxiga dapagliflozin from Bristol-Myers Squibb Co. (NYSE:BMY) and partner AstraZeneca plc (LSE:AZN; NYSE:AZN) as an add-on therapy to treat Type II diabetes. The committee said there was "significant uncertainty" about the validity of meta-analyses showing the clinical effectiveness of Forxiga compared to active comparators in combination therapies. The committee also said it could not "adequately replicate" the partners' economic model, which showed Forxiga had an incremental cost-effectiveness ratio (ICER) of less than L30,000 ($47,223) per quality-adjusted life year (QALY) gained compared with other anti-diabetic drug therapies. NICE requested that the partners submit revised analyses. ...